Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor

Zelalem Temesgen; Judith E Feinberg

Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor

Curr Opin Investig Drugs. 2006 Aug;7(8):759-65.

Authors

Zelalem Temesgen¹, Judith E Feinberg

Affiliation

¹ Mayo Clinic, Division of Infectious Diseases, 200 First Street SW, Rochester, MN 55905, USA. [email protected]

PMID: 16955688

Abstract

Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.

Publication types

Review

MeSH terms

Animals
Clinical Trials, Phase II as Topic
Drug Evaluation, Preclinical
Gene Products, gag / antagonists & inhibitors*
HIV Infections / drug therapy*
HIV Infections / metabolism
HIV-1 / metabolism*
Humans
Succinates / adverse effects
Succinates / pharmacokinetics
Succinates / pharmacology*
Succinates / therapeutic use
Triterpenes / adverse effects
Triterpenes / pharmacokinetics
Triterpenes / pharmacology*
Triterpenes / therapeutic use

Substances

Gene Products, gag
Succinates
Triterpenes
bevirimat